The Food and Drug Administration yesterday updated its FAQs on the emergency use authorization of remdesivir for use on certain hospitalized COVID-19 patients.

The document includes information on the changes to Gilead’s fact sheets for health care providers and patient caregivers.

FDA this week also posted a patient-and-consumer-focused FAQ about SARS-CoV-2 antibody, or serology, testing, including a guide to understanding test results and where to obtain them.

Related News Articles

Headline
A series of free videos from Med Tac offers guidance on how essential workers and the public can stay safe during the COVID-19 public health emergency.…
Headline
The AHA, American Medical Association, American Society of Health-System Pharmacists, and United States Pharmacopeia last week convened a virtual summit to…
Headline
The National Institutes of Health today announced clinical trials to investigate the safety and efficacy of a synthetic antibody therapy in COVID-19 patients.…
Headline
The Centers for Medicare & Medicaid Services will allow health insurers to offer premium reductions for individuals with 2020 coverage in the individual…
Headline
The Department of Health and Human Services Friday released specifications for reporting certain COVID-19 laboratory data as required by the Coronavirus Aid,…
Headline
The U.S. District Court for the Southern District of New York yesterday ruled against the Department of Labor regarding its regulations related to certain…